Cortexin, nootropil and cerebrolysin have been used as neuroprotective medications in the acute period of ischemic stroke (IS). Clinical efficacy of cortexin and nootropil has been compared in 2 therapeutic series in 35 patients and that of cortexin and cerebrolysin--in 45 patients. The efficacy was assessed using several clinical and psychometric scales with statistical processing of the results. The data obtained suggest that in patients with moderate IS the drugs exert a similar and rather marked effect which was stronger comparing to the treatment without these drugs. At the same time, a domestic neuroprotector cortexin has some advantages, especially with regard to the absence of side-effects and "price-dose-therapeutic effect" criterion.